These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3149210)

  • 21. Diurnal variation in valproic acid clearance.
    Bauer LA; Davis R; Wilensky A; Raisys V; Levy RH
    Clin Pharmacol Ther; 1984 Apr; 35(4):505-9. PubMed ID: 6423338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of time, injury, age and ethanol on interpatient variability in valproic acid pharmacokinetics after traumatic brain injury.
    Anderson GD; Temkin NR; Awan AB; Winn HR
    Clin Pharmacokinet; 2007; 46(4):307-18. PubMed ID: 17375982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults.
    Bano G; Gupta S; Gupta KL; Raina RK
    J Assoc Physicians India; 1990 Sep; 38(9):629-30. PubMed ID: 2266076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circadian rhythm of embryotoxicity induced by sodium valproate in mice.
    Ohdo S; Watanabe H; Ogawa N; Yoshiyama Y; Sugiyama T
    Eur J Pharmacol; 1995 Oct; 293(3):281-5. PubMed ID: 8666048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Serum valproic acid concentrations in monotherapy with 1, 2 and multiple administrations per day].
    Stefan H; Burr W; Fröscher W
    Nervenarzt; 1986 Nov; 57(11):640-8. PubMed ID: 3100971
    [No Abstract]   [Full Text] [Related]  

  • 26. Relative bioavailability and stability of extemporaneously prepared valproic acid emulsion.
    Veerman MW; Hatton RC; Knight ME
    Clin Pharm; 1991 May; 10(5):382-4. PubMed ID: 2049900
    [No Abstract]   [Full Text] [Related]  

  • 27. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.
    Dutta S; Reed RC
    Clin Drug Investig; 2006; 26(12):681-90. PubMed ID: 17274675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-dependent kinetics viii: absence of diurnal oscillations in valproic acid disposition following single dose administration to rhesus monkey.
    Levy RH; Viswanathan CT; Lockard JS
    J Pharm Sci; 1982 Jun; 71(6):723-5. PubMed ID: 6808115
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone.
    Paulzen M; Eap CB; Gründer G; Kuzin M
    J Clin Psychopharmacol; 2016 Feb; 36(1):90-2. PubMed ID: 26658079
    [No Abstract]   [Full Text] [Related]  

  • 30. Valproic Acid Suppositories for Management of Seizures for Geriatric Patients.
    DiScala SL; Tran NN; Silverman MA
    Consult Pharm; 2016; 31(6):313-9. PubMed ID: 27250072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults.
    Bauer LA; Davis R; Wilensky A; Raisys V; Levy RH
    Clin Pharmacol Ther; 1985 Jun; 37(6):697-700. PubMed ID: 3924464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Carnitine on Valproic Acid Pharmacokinetics in Rats.
    Katayama H; Mizukami K; Yasuda M; Hatae T
    J Pharm Sci; 2016 Oct; 105(10):3199-3204. PubMed ID: 27499337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic drug monitoring of valproic acid].
    Kohda Y
    Nihon Rinsho; 1990 Feb; 48 Suppl():1130-3. PubMed ID: 2113114
    [No Abstract]   [Full Text] [Related]  

  • 34. Disposition of valproic acid in self-poisoned adults.
    Wilimowska J; Florek E; Piekoszewski W
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):22-6. PubMed ID: 16867166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Interaction of valproic acid and erythromycin].
    Sánchez Romero A; Onsurbe Ramírez I
    An Esp Pediatr; 1990 Jan; 32(1):78-9. PubMed ID: 2109560
    [No Abstract]   [Full Text] [Related]  

  • 36. An adult onset patient with Kleine-Levin syndrome responding to valproate.
    Adlakha A; Chokroverty S
    Sleep Med; 2009 Mar; 10(3):391-3. PubMed ID: 19062339
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacokinetics and tissue distribution of N-(2-hydroxyphenyl)-2-propylpentanamide in Wistar Rats and its binding properties to human serum albumin.
    Correa-Basurto AM; Romero-Castro A; Correa-Basurto J; Hernández-Rodríguez M; Soriano-Ursúa MA; García-Machorro J; Tolentino-López LE; Rosales-Hernández MC; Mendieta-Wejebe JE
    J Pharm Biomed Anal; 2019 Jan; 162():130-139. PubMed ID: 30236821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diurnal oscillations of CSF valproate in monkey.
    Lockard JS; Viswanathan CT; Levy RH
    Life Sci; 1985 Apr; 36(13):1281-5. PubMed ID: 3920464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats.
    Yu HY; Shen YZ; Sugiyama Y; Hanano M
    Drug Metab Dispos; 1990; 18(1):121-6. PubMed ID: 1970771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valproic acid delayed release (Stavzor).
    Med Lett Drugs Ther; 2009 Apr; 51(1309):27-8. PubMed ID: 19343008
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.